Selectively activated probiologics by the ovarian tumor microenvironment to enable safe and effective therapies

Active Project Grant Awarded Last action

Award ID
HT9425261E232
Recipient
Awarding agency
Obligated
$350,000

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date 11% complete
Place of performance
Carlsbad, CA 92011, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The Defense Health Agency awarded Voro Therapeutics, Inc. $350,000 on August 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop selectively activated probiologics by the ovarian tumor microenvironment to enable safe and effective therapies. Performance is located in Carlsbad, California. The award period runs through July 31, 2028. This Project Grant funds basic, applied, and advanced biomedical research to transform healthcare for Service Members and the American public through innovative research and to investigate medical solutions for battlefield conditions.

Quick answers

Who received award HT9425261E232?

HT9425261E232 was awarded to Voro Therapeutics, Inc. by Defense Health Agency (Department of Defense) on August 1, 2026.

How much is award HT9425261E232 worth?

$350,000 has been obligated on HT9425261E232.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login